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Recombinant adenovirus vectors and MVAvectors were used in prime boost vaccine regimens to address the impact of repeated immunizations
on transgene product-specific CD8+ T cell frequencies, phenotypes, function, and localization. We show that a regimen with three immunizations
incorporating MVA, human adenovirus serotype 5 and chimpanzee-derived adenoviruses serotype 68 or 7 yields high transgene product-specific
CD8+ T cell frequencies in spleen, blood, lymph nodes, and peritoneal lavage. Furthermore, upon triple immunization increased frequencies of
transgene-specific T cells were measured at mucosal sites such as mesenteric lymph nodes, intestinal epithelium, and Peyer's patches. Multiple
dose vaccine regimens that markedly increase functionally active transgene-specific T cells and target them to the appropriate ports of entry may
be important in protection against pathogens such as HIV-1.
© 2007 Elsevier Inc. All rights reserved.Keywords: Vaccine; HIV-1; Prime BoostIntroduction
Commonly, vaccination protocols require multiple immuniza-
tions to achieve robust, protective, and sustained immune
responses. Most research efforts have focused on characterizing
CD8+ T cells induced by primary immunizations. Naive T cells
are activated following first exposure to antigens, and they pro-
liferate before assuming effector functions to eliminate the anti-
gen, after which most effector cells undergo apoptotic cell death
and numbers of antigen-specific CD8+ T cells decline sharply
(Badovinac et al., 2002). The remaining CD8+ T cells form the
memory pool that can rapidly respond once they re-encounter
antigen (Ahmed and Gray, 1996; Sprent and Tough, 1994, 2001).
Memory CD8+ T cells can be broadly classified as effector
memory or central memory cells, TEM and TCM, respectively.⁎ Corresponding author.
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doi:10.1016/j.virol.2007.05.028These distinctions are based on phenotypic markers and
proliferation rates upon re-encounter of antigen. TEM express
low levels of lymph node homing receptor CD62L and are thus
found primarily in non-lymphoid tissues. They are immediately
cytolytic but have low proliferative capacity. TCM express high
levels of CD62L and are primarily found in lymphoid tissue.
They require a longer period to reacquire cytolytic function but
have a high proliferative potential (Sallusto et al., 1999;
Weninger et al., 2002; Wherry et al., 2003b).
Depending on the pathogen, different CD8+ T cell subsets
have been shown to provide protection against challenge.
Effector CD8+ cells are best suited to immediately eliminate
infected cells because they are present in high numbers and can
immediately assume effector functions including cytolysis
(Zinkernagel and Hengartner, 2006). TEM are present at
lower numbers, but they are fully activated and can localize
to ports of viral entry. They can therefore attack virus-infected
cells early immediately upon invasion (Cerwenka et al., 1999;
Huster et al., 2006). Alternatively, after an initial immunization,
TCM are maintained at stable frequencies for the lifetime of an
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antigen. Since they are capable of homing to lymphatic tissues,
TCM cells would be expected to protect against systemic
infections that have moved past the port of entry and that would
require significant CD8+ T cell expansion for protection
(Wherry et al., 2003b). A vaccine that induces a combination
of these CD8+ subtypes might protect against infections such as
HIV-1 by rapidly eliminating infected cells at the port of entry
through the activity of TEM cells, and then also providing a
second wave of defense against viruses that escape the initial
immune response, through the activity of TCM cells within the
lymph nodes.
Recently it has been shown that memory CD8+ T cells differ
substantially depending on the number of immunizations, and
that secondary and tertiary responses result in the generation of
memory CD8+ T cells which retain effector-like phenotypes and
show preferential accumulation in non-lymphoid tissues,
indicating that prime boost vaccination strategies not only
increase frequencies of responding CD8+ T cells but also may
have consequences on CD8+ T cell quality, which in turn may
impact the efficacy of T cell-inducing vaccines (Jabbari and
Harty, 2006; Masopust et al., 2006).
Recombinant replication-defective adenoviral (Ad) vectors
are being developed as vaccine vehicles to immunize against a
number of pathogens (Casimiro et al., 2004; Gao et al., 2006;
Jaiswal et al., 2003; Kobinger et al., 2006; Perkins et al., 2006;
Tims et al., 2000). These vectors are promising because they
generate strong transgene-specific CD8+ T cell responses in
both animal models and people (Casimiro et al., 2002; Emini,
2002; Fitzgerald et al., 2003; Reyes-Sandoval and Ertl, 2004).
While single administrations of these vaccines can generate
potent and sustained transgene-specific CD8+ T cell responses,
heterologous boosts are nevertheless being explored to increase
the magnitude of the immune response (Casimiro et al., 2004;
Reyes-Sandoval and Ertl, 2004; Shiver et al., 2002). Here we
address phenotypic and functional characteristics of antigen-
specific CD8+ T cells after sequential immunizations using
combinations of human Ad of the serotype 5 (AdHu5), simian
adenoviruses of serotype 68 (AdC68) or 7 (AdC7), and/or
modified vaccinia Ankara (MVA) viruses. Furthermore, since
much of the world's human population has pre-existing
immunity to AdHu5, we also evaluate the frequencies of
CD8+ T cells that are generated upon vaccine regimens
incorporating both the human and chimpanzee-derived vectors
in mice that have been pre-exposed to AdHu5. Our data show
that repeated immunization not only increases the frequencies
of antigen-specific CD8+ T cells but also enhances their
functional properties and allows for more efficient trafficking of
the responding cells to mucosal sites.
Results
Sequential immunizations increase frequencies of
antigen-specific CD8+ T cells
Antigen-specific CD8+ T cell frequencies and migration
patterns were analyzed following vaccination of BALB/c micewith three different vaccine carriers, i.e., AdC68, AdHu5, and
MVA, all expressing HIV-1 gag given in different orders
(outlined in Fig. 1A). Mice were primed with either AdHu5gag
or AdC68gag at a relatively low dose of 1×109 vp per mouse.
After 60 days mice were boosted with a heterologous vector.
Mice that were primed with AdHu5gag were boosted with
AdC68gag or 106 pfu MVAgag, and 5 months later they re-
ceived a third immunization with either MVAgag or AdHu5gag,
respectively. Correspondingly, mice that were primed with
AdC68gag were boosted with either AdHu5gag or MVAgag
and then boosted a second time with MVAgag or AdHu5gag,
respectively. Cohorts of mice that received one, two, or three
vaccines were sacrificed at different time points after each
immunization (Fig. 1A). Frequencies of CD8+ Tcells producing
IFN-γ in response to a peptide carrying the immunodominant
epitope of gag were measured by intracellular cytokine staining
(ICS) from spleens, blood, peritoneal lavage, and draining
lymph nodes. Fig. 1B shows that after a single immunization,
resulting frequencies of antigen-specific CD8+ T cells produ-
cing IFNγ were moderate after both AdHu5gag and AdC68gag
administration. This was expected considering the low dose of
vector. The first boost increased frequencies when compared to
those obtained at the same time (i.e., day 150) from mice that
had only been immunized once. Nevertheless, upon a single
immunization with AdC68, frequencies increased without
further immunization between days 150 and 365 above those
seen after a double immunization on day 150. Ad vectors persist
and we assume that the increase in frequencies at a late time
point after a single immunization may reflect ‘internal boosts’
by continued low-level production of antigen by the persisting
AdC68gag vector genome. In AdHu5gag primed mice, the first
boost with either AdC68gag or MVAgag yielded a more
impressive increase in frequencies of gag-specific CD8+ T cells
in most compartments, except for lymph nodes. The third
immunization resulted in a substantial increase in CD8+ T cell
frequencies in AdC68gag primed mice in all compartments
tested regardless of the order of the booster immunizations. In
AdHu5 primed animals, a third immunization increased
frequencies in spleens and lymph nodes above those seen
after a second immunization but was relatively ineffective in
increasing the frequencies of gag-specific CD8+ T cells in blood
and peritoneal lavage of the AdHu5gag/MVAgag/AdC68gag
immunized mice.
HIV-1 most commonly gains entry through the mucosal
surfaces of the genital tract and then rapidly spreads from there
to lymphatic tissues. Lymphocytes residing in the intestinal tract
provide a particularly rich source of susceptible CD4+ T cells
which rapidly become infected upon systemic spread of HIV-1
and are then depleted. It is thus important that T cell-inducing
HIV-1 vaccines generate an immunological barrier at mucosal
sites. To test whether single or multiple immunizations with the
viral vectors induced CD8+ T cells that homed to mucosal sites,
we tested lymphocytes isolated from the same groups of mice
shown in Fig. 1A from mesenteric lymph nodes, Peyer's
patches and the intraepithelial layer of the intestine (inner
epithelial lymphocytes–IEL) by ELISpot assays with an MHC
class I-binding gag peptide for the production of IFN-γ. As
Fig. 1. Sequential immunizations increase frequencies of antigen-specific T cells. (A) Schedule of immunization of BALB/c mice and time points of CD8+ T cell
analyses. (B and C) Groups of 4 BALB/c mice were immunized with 1×109 vp of indicated viruses encoding HIVgag. At different times post-immunizations
lymphocytes were isolated from spleen, popliteal and inguinal lymph nodes (LN), blood, peritoneal lavage (PL), mesenteric lymph nodes (MLN), Peyer's patches
(PP), and small intestine and assayed for IFNγ production by ICS (B) or ELISpot (C) in response to gag peptide stimulation. The Xs connected by a line represent
CD8+ T cell frequencies over time in mice that had a single immunization (either AdC68 or AdHu5), day 150 bars show frequencies after a single boost tested on day
150 after priming (filled bar: boosted with either AdHu5 or AdC68; gray bar: boosted with MVA), day 365 bars shows data after the second boost (filled bar: boosted
with MVA; gray bar: boosted with AdHu5 in the AdC68 primed group or AdC68 in the AdHu5 primed group) tested on day 365 after priming. In all experiments
shown in this figure and subsequent figures, splenocytes from individual mice were analyzed and the graphs show either the average result, or in case of phenotypes
(Fig. 3A) a representative result from 4 to 5 samples. Lymphocytes from blood and the other tissues were pooled. For spleens, as noted in text when comparing values
from a single immunization to boosts or from one boost to two boosts, pb0.03.
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Fig. 2. An immunization regimen in which three heterologous vectors were
given consecutively exhibits marked increase of antigen-specific T cells in
gut mucosa. (A) Schedule of immunization of BALB/c mice and time points
of CD8+ T cell analyses. (B) Groups of 3–5 BALB/c mice were immunized
with 1×109 vp AdC68HIVgag then boosted with the same dose of AdC7
and then AdHu5. All vectors encoded HIVgag. CD8+ T cells were isolated
at indicated times from different tissues and stained with an antibody to CD8
and an HIVgag tetramer. The Xs connected by lines show gag-specific CD8+
T cell frequencies in mice immunized once, while bars on day 115 show
frequencies from mice that were boosted once and tested 115 days after
priming. Bars on day 210 show frequencies after the second boost on day
210 after priming.
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ELISpot on cells isolated from spleens, blood, lymph nodes, or
peritoneal lavage mirrored those determined by ICS. The third
immunization increased frequencies in both AdC68gag and
AdHu5gag primed mice in all tissues examined except the
CD8+ T cells isolated from peritoneal lavage of mice
immunized with either AdHu5 or AdC68 and using MVA as
the first boost. In mucosal tissues modest frequencies of gag-
specific T cells could be detected after the first and second
immunization. They increased markedly after the third
immunization (p values b0.05). IELs are shown at the day
365 time point after a single immunization and after the triple
immunization. Gag-specific T cells were not detected in IELs
after a single immunization with either AdC68gag or AdHu5-
gag but were readily detectable after a triple immunization.
To substantiate this finding and to ensure that this
observation was not specific for immunization regimens that
combined Ad vectors with MVA vectors, we conducted a
different immunization regimen in which mice were immunized
only with Ad vectors, starting with an AdC68gag prime. Two
months later some groups were boosted with a gag-expressing
vector derived from the chimpanzee Ad serotype 7 (AdC7),
which is serologically distinct from AdC68. Approximately
2 months after the second immunization some of the animals
were vaccinated a third time with an AdHu5gag vector (Fig.
2A). All of the vectors were given at 109 vp i.m. Mice that
received one, two, or three immunizations were sacrificed at
different times thereafter, and frequencies of gag-specific CD8+
T cells were measured in spleens, blood, mesenteric lymph
nodes, Peyer's patches, and lymphocytes of the lamina propria
by staining with a gag-specific tetramer and an antibody to
CD8. As shown in Fig. 2B, a single immunization with
AdC68gag induced low frequencies of gag-specific CD8+ T
cells in mesenteric lymph nodes and transient frequencies in
Peyer's patches and the lamina propria. A second immunization
did not increase frequencies in mucosa-associated tissues above
those seen at the peak after priming, although a robust booster
effect was seen in spleens and blood. The third immunization
increased frequencies in all compartments and this increase was
disproportionably higher in mucosal-associated tissues than in
spleens or blood.
History of antigen exposure changes the phenotypes of
antigen-specific memory CD8+ T cells
In addition to measuring frequencies of CD8+ T cells
induced by one, two, or three immunizations, we analyzed
antigen-specific CD8+ Tcells for their expression of cell surface
markers. Lymphocytes from spleens, draining lymph nodes,
blood, and peritoneal lavage were obtained from animals shown
in Fig. 1A, while lymphocytes from mesenteric lymph nodes
and Peyer's patches were obtained from animals shown in Fig.
2A. Figs. 3A and B show results obtained with lymphocytes
from spleens, blood, and peritoneal lavage after one, two, or
three immunizations (Fig. 3A shows data for the regimen
beginning with an AdC68gag prime). Fig. 3C shows results
from mesenteric lymph nodes and Peyer's patches from animalsthat received three immunizations. Lymphocytes were stained
with a tetramer specific for an epitope from HIVgag, anti-CD8,
-CD62L, -CD27, and -CD127.
CD62L is a homing molecule that targets lymphocytes to
lymph nodes. TCM CD8+ T cells, as opposed to TEM, express
high levels of CD62L. CD8+ T cells induced by a single vacci-
nation are CD62Llo during the effector to effector memory
phase, but then they upregulate CD62L once they become cen-
tral memory cells. After a single immunization with AdC68gag
or AdHu5gag, the majority of antigen-specific CD8+ T cells in
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least 150 days. In fact by day 150 after immunization only about
30% of the cells had a CD62Lhi phenotype in spleens (Figs. 3A
and B). In contrast by 1 year post-immunization most cells in
spleen and lymph nodes up-regulated CD62L and at that time
about 80% of the cells were CD62Lhi. A higher percentage
remained CD62Llow in blood and peritoneal lavage. After the
first booster immunization, a portion of gag-specific CD8+ T
cells remained CD62Llow and by 90 days after the boost (corre-
sponding to 150 days after priming) on average 60% of gag-
specific CD8+ T cells had a CD62Llo phenotype, with numbers
ranging from 31% to 53% for the different prime boost com-
binations (Figs. 3A and B). There was no difference between the
groups that received either AdC68gag or AdHu5gag first. After
three immunizations, a substantial portion (17–49% depending
on the immunization regimen and tissue) of antigen-specific
CD8+ T cells remained CD62Llo when tested 150 days after the
last immunization (365 days after priming). Gag-specific CD8+
T cells from mesenteric lymph nodes and Peyer's patches
expressed low levels of CD62L early after the third immuni-
zation. By day 97 after the third immunization, the majority of
gag-specific CD8+ cells from mesenteric lymph nodes were
CD62Lhi while most of them were CD62Llo in Peyer's patches,
suggesting that the latter remained more activated.Fig. 3. History of antigen exposure does not result in significant changes in phenotype
blood, and draining lymph nodes (LN) of mice diagrammed in Fig. 1Awere stained wi
and HIVgag tetramer. (A) The data set represents mice that were primed with AdC68
(M) encoding HIVgag. The black line shows fluorescent intensity of tet+ CD8+ T cell
(B) Frequencies of gag-specific CD8+ T cells from animals that were first immunized
by lines show frequencies over time in spleen of mice that had a single immunization,
and tested on day 150 after priming. The bars at d365 show frequencies after the seco
mesenteric lymph nodes (MLN) and Peyer's patches (PP) from mice that received 3
tet+ CD8+ T cells and the shaded curve shows that of naive CD8+ T cells.CD27 is a marker for T cell activation that is upregulated
once CD8+ Tcells transition to memory. After one, two, or three
immunizations, most cells in spleens expressed high levels of
CD27. However, a second population that expressed inter-
mediate levels of CD27 was detected. This population was more
prominent in blood on days 60 and 150 after one immunization
and then also after the 2nd and 3rd immunization. The CD27int
phenotype was not seen in lymphocytes harvested from
draining lymph nodes, peritoneal lavage (data not shown), or
mesenteric lymph nodes but was observed in gag-specific CD8+
T cells from Peyer's patches.
Lastly, we measured expression of the IL-7 receptor,
CD127, a memory cell marker. After one immunization with
AdC68 a substantial proportion of gag-specific CD8+ T cells
initially expressed low levels of CD127. By day 365 all of the
gag-specific CD8+ T cells in spleen and blood expressed
levels of CD127 that were higher than those of tetramer
negative cells. After the second immunization most cells were
CD127hi when tested 3 months later. In spleens levels were
higher than on the control population while in blood levels
were comparable. After the third immunization, cells in
spleen and blood expressed high levels of CD127 that were
comparable to those seen 1 year after a single immunization.
Cells isolated from mesenteric lymph nodes and Peyer'ss of antigen-specific CD8+ T cells. (A and B) Lymphocytes isolated from spleen,
th anti-CD8. They were also stained with antibodies to CD62L, CD27, or CD127
gag and then subsequently boosted with combinations of AdHu5 (H) and MVA
s and the shaded curve shows that of naive CD8+ T cells. n.d. is not determined.
with AdC68gag or AdHu5gag. Data shown are for tet+ CD8+ cells. Xs connected
while bars at d150 show frequencies from spleens of mice that were boosted once
nd boost on day 365 after priming. (C) Phenotypes of lymphocytes isolated from
immunizations as described in 2A. The black line shows fluorescent intensity of
Fig. 3 (continued ).
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3 months after the third immunization.
Notably, the kinetics of CD62L low expression to high
expression (a measure of TEM to TCM conversion) was
increased through multiple immunizations, which differs from
two recent publications that reported an increase of CD8+ Tcells expressing low levels of CD62L after multiple immuniza-
tions (Jabbari and Harty, 2006; Masopust et al., 2006). In our
studies, after a single boost in both spleen and blood a
comparison of time points post-antigen exposure shows that
more antigen-specific CD8+ T cells are CD62Lhi at d90 after the
boost than on day 150 after the single immunization. This effect
Fig. 3 (continued ).
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third immunization. A markedly higher fraction of antigen-
specific CD8+ T cells are CD62Lhi on day 150 after the third
vaccine dose than on day 150 after a single dose of vector
administration.
History of antigen exposure changes the functionality of
antigen-specific CD8+ T cells
To determine if multiple immunizations affected the
functions of gag-specific CD8+ T cells, we tested transgene
product-specific CD8+ T cells from mice that received one, two,
or three immunizations (mice from Fig. 1A, AdC68 prime) for
cells that expressed gag-specific T cell receptors as measured by
staining with a tetramer (tet), and that secreted IFN-γ in
response to the gag peptide. After a single immunization a
portion of gag-specific tet+ CD8+ T cells failed to secrete IFN-γ
when tested after 2, 5, or 12 months (Fig. 4A). This was
particularly pronounced with cells isolated from blood or
peritoneal lavage. A second immunization did not increase the
proportion of tet+ positive to IFN-γ secreting CD8+ T cells
while, in contrast, this proportion increased markedly after a
third immunization.
The same cells were tested for concomitant production of
IFN-γ and TNF-γ (Fig. 4B). The proportion of gag-specific
CD8+ T cells that secreted both TNF-γ and IFN-γ was high at
most time points after one, two, or three immunizations in the
spleen, and at late time points after a single immunization in
lymph nodes as well as after one or two boosts. The proportion
of CD8+ T cells secreting both cytokines decreased over time in
blood and peritoneal lavage after a single immunization. One or
two booster immunizations reversed this trend and increased the
proportion of gag-specific CD8+ T cells that secreted both
cytokines in these compartments.
Repeated immunization does not fully rescue the CD8+ T cell
response in animals pre-exposed to the viral vaccine vector
Most humans are naturally infected with AdHu5 vectors
during childhood, and ∼40% of adults residing in the US and
up to 90% of those living in Central Africa have circulating
neutralizing antibodies to AdHu5 virus. Such antibodies inhibit
cellular uptake of vaccines based on AdHu5 virus and as a
consequence reduce transgene product-specific immune
responses. To test whether CD8+ T cell responses to AdHu5
vaccines could be rescued by repeated immunizations, we pre-
exposed groups of BALB/c mice with 108 pfu (which corre-sponds to approximately 2–5×1010 vps) of an AdHu5 vector
expressing an irrelevant antigen. Three weeks later, when mice
had developed neutralizing antibody titers to AdHu5 virus
comparable to those commonly found in human sera (Xiang et
al., 2006), mice were vaccinated with AdHu5gag, AdC6gag, or
AdC68gag vectors. Gag-specific CD8+ T cell responses were
tested 3 months later from different compartments and
additional groups of mice were then boosted with either
AdHu5gag or AdC6gag (Fig. 5A) and CD8+ T cell responses to
gag were measured 3 months later (Fig. 5B). AdHu5 pre-
exposed animals as reported previously (Fitzgerald et al., 2003)
showed a marked reduction in gag-specific CD8+ T cell
responses upon vaccination with the AdHu5 vector. Pre-
exposure to AdHu5 caused a slight reduction of the CD8+ T
cell response to the chimpanzee Ad vectors; this reduction is
caused by CD8+ T cells that cross-react between the different
Ad serotypes (Fitzgerald et al., 2003). Booster immunization
with AdHu5gag in AdHu5 pre-exposed mice that had been
primed with AdC6gag or AdC68gag failed to increase CD8+ T
cell frequencies in any of the compartments tested. Regardless
of pre-exposure, in AdHu5gag-primed animals, booster immu-
nization with AdC6gag (or AdC68gag, not shown) resulted in
an increase of frequencies of gag-specific CD8+ T cells. In
blood and lymph nodes, frequencies in non-pre-exposed and
pre-exposed animals primed with AdHu5gag were comparable
after the boost, while in spleens and peritoneal lavage, pre-
exposed mice had lower frequencies than those that had not
been pre-exposed. This result suggests that for individuals with
neutralizing titers to AdHu5 virus, the AdHu5 vector may be
more useful as a priming rather than a booster vaccine.
Discussion
The goal of vaccination strategies is to achieve protective
memory responses. Most successful vaccines to date rely on the
induction of neutralizing antibodies. Unfortunately, induction of
protective levels of antibodies has not yet been achieved with
HIV-1 vaccines. Thus, the focus for HIV-1 vaccines has shifted
to induction of cellular immune responses, namely memory
CD8+ T cells. Much of the immunological data generated so far
have focused on CD8+ T cell memory responses resulting from
a single immunization, while clinical trials with HIV-1 vaccines
are generally based on prime boost regimens. It is therefore
crucial to elucidate the effects of multiple immunizations on the
quality of memory CD8+ T cells. It was recently reported that
after repeated immunizations, CD8+ T cells show a delayed
conversion to resting central memory cells, retain more effector-
like properties, and exhibit preferential migration to non-
lymphoid sites. These studies were conducted with a number of
immunogens including lymphocytic choriomeningitis virus,
Listeria monocytogenes vectors, and vesicular stomatitis virus
(VSV) vectors (Jabbari and Harty, 2006; Masopust et al., 2006).
These vectors have in common that upon a brief phase of
replication they are cleared completely from the immune
system. Also, none of these vectors in the form used in these
studies are considered suited for clinical development, although
more attenuated forms of VSV vectors are being explored for
Fig. 4. Multiple immunizations result in CD8+ T cells with increased functionality. (A) CD8+ T cells isolated from mice primed with AdC68gag (described in Fig. 1A)
were used to compare the percentage of CD8+ T cells that secreted IFNγ (left panel) and the percentage that were tet+ (right panel). Lymphocytes were isolated from
spleen, draining lymph nodes (LN), blood (BL), and peritoneal lavage (PL). The Xs connected by lines show frequencies in mice after a single immunization with
AdC68gag, bars at d150 represent frequencies after a single boost tested on day 150 after priming (filled bar is boosted with AdHu5 and shaded bar is boosted with
MVA), bars at d365 represent data after a second boost tested on day 365 after priming (filled bar is boosted with MVA and shaded bar with AdHu5). (B) The same
cells as panel A were assayed by ICS for percentage that secreted both IFNγ and TNFα from both the AdC68gag and AdHu5gag primed groups.
163N. Tatsis et al. / Virology 367 (2007) 156–167use as vaccines to HIV-1 (Publicover et al., 2005; Ramsburg
et al., 2004).
In our studies, we used replication-defective vectors. Two of
these vector prototypes, i.e., MVA and AdHu5, are already in
clinical trials and the chimpanzee Ad vectors are being
considered for clinical trials. The Ad vectors, unlike MVA
vectors, induce a very potent CD8+ T cell response after a single
application, and unlike responses observed with immunogens
that are rapidly cleared, CD8+ T cell responses induced by Ad
vectors fail to contract and commonly even increase over time
in some compartments. This most likely reflects that genomes
of Ad vectors persist in different cell types, including activated
CD8+ T cells, for prolonged periods (manuscript in press,
Blood). They remain transcriptionally active and the low
amounts of antigen that are produced for several months appear
to continuously recall memory CD8+ T cells into the effector T
cell pool. Levels of antigen produced by persisting Ad vectors
are too low to cause immunological exhaustion or a pronounced
increase in CD8+ T cell frequencies, which can readily beincreased by a second or third immunization with a hetero-
logous vector. Nevertheless, the constant exposure to low levels
of antigen results in an unusual phenotype of Ad vector induced
‘memory’ CD8+ T cells, most of which remain CD62Llo for
several months. Furthermore, the migration pattern of Ad vector
induced CD8+ T cells is distinct, as Ad vectors, unlike other
immunogens, induce high frequencies of CD8+ T cells in
spleen, blood, and non-lymphoid tissues but only modest
responses in lymph nodes. This again most likely reflects that a
continuous presence of antigen maintains a cohort of activated
CD8+ T cells that are excluded from crossing the high
endothelial venules of lymph nodes, which requires expression
of CD62L.
Booster immunization with heterologous vectors increased
the frequencies of transgene product-specific CD8+ T cells,
although the effectiveness of the first boost was clearly
influenced by the type and sequence of the immunogens. An
immunization protocol of AdC68 followed by MVA affected
only a marginal boost while AdC68 followed by AdC7, or
Fig. 5. Effects of repeated immunization on the CD8+ T cell response in animals
pre-exposed to viral vector. A group of BALB/c mice was pre-exposed to
AdHu5 expressing rabies glycoprotein. Three weeks after exposure, titers to
AdHu5 were measured and found to be between 1:80 and 1:360. Mice that were
or were not pre-exposed to AdHu5 were then primed with 1×109 vp of the
indicated vectors expressing HIVgag, and 90 days post-prime lymphocytes were
isolated from spleen, draining lymph nodes (LN), blood, and peritoneal lavage
(PL) and tested for IFNγ production upon stimulation with a gag peptide by ICS.
The remaining mice were boosted with vector. AdHu5 primed mice were
boosted with AdC6, mice primed with AdC6 or AdC68 were boosted with
AdHu5. On day 90 after the second boost, lymphocytes were isolated from
boosted mice, as well as mice that did not receive a boost, were assayed for IFNγ
production upon stimulation with a gag peptide by ICS. Shaded bars indicate
non-AdHu5 pre-exposed mice and solid bars represent AdHu5 pre-exposed
mice.
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frequencies. In a three consecutive dose immunization, the
order of the different vectors appeared to play a lesser role. All
triple immunization protocols that we have tested thus far,
including those that used DNA vaccines for priming (data not
shown), resulted in frequencies of CD8+ T cells in spleen,
blood, and lymph nodes that were well above those seen after asingle immunization. In a series of experiments not shown in
this manuscript we compared regimens in which a poxvirus
vector (based on vaccinia virus strain Copenhagen) was given
either for priming or booster immunization in combination with
an Ad vector. The magnitude of the transgene product-specific
CD8+ T cell response obtained after the second immunization
was very similar regardless of the order in which the two
different vaccine constructs were given (data not shown).
Unlike the above-cited publications, we did not observe the
same effect on CD8+ T cell phenotypes after booster
immunizations using heterologous vectors. In contrast, based
on CD62L phenotyping, we saw an acceleration of TEM to
TCM transition upon multiple immunizations.
We also observed functional changes that may benefit the
efficacy of multiple dose vaccine regimens. Multiple immuni-
zations improved the functionality of the responding CD8+ T
cells. At most time points tested after a single immunization,
less than half of the transgene product-specific CD8+ T cells
identified by staining with a tetramer produced IFN-γ, a key
cytokine in anti-viral defense, upon antigenic stimulation. This
proportion did not change after one booster immunization,
while a second boost strongly increased the proportion of tet+
CD8+ T cells that also produced IFN-γ. This was especially
pronounced for cells isolated from blood and peritoneal lavage.
In these two compartments multiple immunizations also
increased the proportion of CD8+ T cells that secreted both
IFN- γ and TNF-α, again suggesting that repeated exposure to
high levels of antigen increases the functional repertoire of the
responding CD8+ T cells. This latter point is significant since it
has been shown that chronic exposure to antigen, which might
result from persistent adenovirus transgene expression, can lead
to a partially exhausted phenotype (Wherry et al., 2003a).
Transgene product-specific CD8+ T cells induced by Ad
vectors given once or in combination with one boost failed to
home efficiently to mucosa-associated tissues. Frequencies
induced by a single dose of vaccine were low in mesenteric
lymph nodes, Peyer's patches, the lamina propria, or the
intestinal epithelium and failed to increase significantly after a
booster immunization. Notably, after a third immunization,
frequencies in these compartments increased markedly.
Whether this reflects that repeated exposure to high doses of
antigen affects a profound change in the Tcells' homing pattern,
or that overall high frequencies in other compartments including
blood causes a spill-over of T cells into the mucosa associated
tissues remains to be investigated. Regardless of the underlying
mechanism, sustained presence of specific CD8+ T cells at
mucosal sites would be expected to improve the efficacy of a
vaccine to ward off pathogens that invade through mucosal
tissues, or those like HIV-1 that preferentially replicate in
intestinal CD4+ T cells.
To some extent repeated immunization rescued the impaired
CD8+ T cell response elicited by AdHu5 vectors in mice with
pre-existing neutralizing antibodies to AdHu5. This in part
depended on the sequence of the vaccine vectors and the
compartment that was tested. In AdHu5 pre-immune mice, an
AdHu5 boost of mice that had been primed with a chimpanzee
Ad vector was ineffective, while a chimpanzee Ad vector boost
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CD8+ T cell frequencies. In this latter group, it was of interest to
note that after the boost, frequencies of gag-specific CD8+ T
cells remained reduced in spleens and peritoneal lavage of pre-
exposed animals, but in lymph nodes and blood became
comparable to those seen in non-pre-exposed mice. In clinical
trials, immunogenicity of HIV-1 vaccines is assessed by
measuring responses from peripheral blood mononuclear
cells. Our results suggest that results obtained with such
lymphocytes may not accurately reflect the full impact of pre-
existing neutralizing antibodies on AdHu5 vaccines. In
additional experiments not shown in this manuscript, we tested
whether inclusion of a poxvirus vector based on vaccinia virus
could overcome the effect of neutralizing antibodies to AdHu5
upon the immune response to the transgene product expressed
by this vaccine construct. Inclusion of a poxvirus vector in a
prime boost regimen that contained an AdHu5 vector did not
rescue the transgene product-specific CD8+ T cell response in
AdHu5 pre-exposed animals (data not shown).
A clearly stated goal for vaccines that are most direly needed
in developing countries is that such vaccines induce protective
immune responses after a single administration. A single dose
vaccine facilitates broad vaccine coverage and is generally more
cost-effective than multiple dose regimens. For vaccines that
induce protection through neutralizing antibodies, single dose
regimens based on attenuated live viruses are available to
combat a limited number of diseases. For T cell vaccines that
have yet to prove their efficacy in large scale clinical trials, more
complex multiple dose vaccine regimens based on different
types of vectors may be needed to not only achieve sufficiently
high frequencies of CD8+ T cells but to also improve the
functionality of the induced response. Our study shows that
multiple immunizations positively influence the functionality of
antigen-specific CD8+ T cells as well as the localization of these
cells, namely to the mucosa. Further work will determine hether
these characteristics will contribute to protection against HIV-1.
Materials and methods
Mice
Female 6- to 8-week-old BALB/c mice were purchased from
ACE Animals Inc. (Boyertown, PA) and kept at the animal
facility of the Wistar Institute (Philadelphia, PA).
Immunization of mice
Mice were immunized intramuscularly at 6–8 weeks of age
with recombinant viruses diluted in sterile PBS. Animals were
pre-exposed to AdHu5 through i.m. immunization with 108 pfu
of an AdHu5 vector expressing the rabies virus glycoprotein.
Viruses
E1-deleted recombinant AdHu5, AdC68, AdC7, and AdC6
adenoviruses expressed a codon-optimized cDNA encoding a
C-terminus truncated form of HIV-1 Gag protein (Gag37)(Schneider et al., 1997) (gift from G. Pavlakis at NIH/NCI,
Frederick, MD). Construction of these vectors has been
described previously (Pinto et al., 2006; Reyes-Sandoval and
Ertl, 2004; Fitzgerald et al., 2003). Ad vectors were grown on
HEK 293 cells and unless stated otherwise purified by two
rounds of CsCl gradient centrifugation followed by column
purification (Bio-Gel P-6DG). The content of virus particles
(vps) was determined by spectrophotometry, and vector
infectivity was determined by a nested reverse transcription
polymerase chain reaction from RNA isolated from HEK 203
cells infected with serial dilutions of the vectors. Vectors were
also tested for contaminating replication competent adenovirus
and for endotoxin. Vectors used in these studies contained
neither infectious virus nor endotoxin. Recombinant MVA-gag
(vDG022) expresses a synthetic codon-optimized HIV gag
gene, which encodes an antigenic consensus Gag protein
representing HIV subtype B (GenBank AY531263), and a
fluorescent-selectable marker (gfpzeo) from independent early
(modified H5) viral promoters recombined into the MVA
deletion-III locus. Virus was grown on DF-1 chicken embryo
fibroblasts and purified by centrifugation through a 36%
sucrose cushion prior to resuspension in PBS. Infectivity was
determined by plaque assay on DF-1 cells (Garber/Feinberg
manuscript in preparation). The AdHu5 vector expressing the
rabies virus glycoprotein has been described previously (Xiang
et al., 2002).
Intracellular cytokine staining and tetramer staining
Intracellular cytokine staining was performed on lympho-
cytes isolated from spleen, popliteal and inguinal lymph nodes,
blood, and peritoneal lavage as described previously (Fitzgerald
et al., 2003). Antibodies used for ICS were PerCP- or Alexa-
labeled anti-CD8, PE-labeled anti-TNFα, or -IL2 and APC-
labeled anti-IFNγ. For tetramer staining cells were harvested
from indicated tissues, red blood cells were lysed with ACK
lysis buffer (Gibco) treatment for 3 min on ice, washed 3 times
with L-15 media (Gibco) and stained with APC-labeled HIV-1
Gag tetramer (NIH Tetramer Core Facility at Emory), PerCP- or
Alexa-labeled anti-CD8, PE-labeled anti-CD27 or -CD127, and
FITC-labeled anti-CD62L. All antibodies used were obtained
from BD Biosciences (San Jose, CA). For flow cytometry cells
were acquired on a BD FACSCalibur (BD Biosciences, San
Jose, CA) and analyzed using FlowJo software (Ashland, OR).
For marker staining the naive populations were age-matched
unless otherwise noted. All statistics noted used one-tailed
Student t tests.
Isolation of mucosal tissue
Mesenteric lymph nodes (MLN) and Peyer's patches (PP)
were dissociated against metal screens and washed with 10%
FBS in 1× HBSS. After all visible PPs were removed from
small intestines, the intestines were cut longitudinally and then
into 1-cm pieces. They were incubated with HBSS/HEPES
bicarbonate buffer containing 10% fetal bovine serum (FBS) for
15 min with slow stirring, 5 times, to rid the intestines of
166 N. Tatsis et al. / Virology 367 (2007) 156–167intraepithelial lymphocytes. Final preparations of IELs were
purified on a 40–70% Percoll gradient (2000 rpm at 10 °C for
20 min). Lamina propria lymphocytes (LPL) were isolated from
remaining intestines by treatment with collagenase (3 mg
collagenase P per 3 ml media per mouse). Final preparations of
LPL were purified on a 40–100% Percoll gradient (2000 rpm at
10 °C for 20 min).
ELISpot assays
96-well Millipore (Billerica, MA) PVDF plates were coated
with mouse anti-IFN-gamma capture antibody diluted in PBS
and incubated overnight at 4 °C. After washing with PBS, plates
were blocked with complete RPMI-1640 with 10% FBS for 2 h
at 37 °C. Lymphocytes were added in triplicate and stimulated
with the BALB/c-specific 9-mer peptide AMQMLKETI and co-
stimulatory molecules mouse anti-CD28 and mouse anti-CD49d
(BD Pharmingen) for 18–20 h at 37 °C with 5% CO2. Cells were
removed and plates were washed with 0.01% Tween20/PBS and
incubated with biotin-labeled secondary antibody in 5% FBS in
0.01% Tween/PBS for 2 h at room temperature. Plates were
washed and streptavidin alkaline phosphatase was added at
room temperature for 1 h, and the spots were developed by
adding BCIP/NBT developer to each well for 5 min at room
temperature. Plates were washed in water and dried before
counting the spots using the C.T.L. Series 3A Analyzer and
ImmunoSpot 3.2 (Cellular Technology Ltd, Cleveland, OH).
Data from unstimulated cells were used as background control
and values were subtracted from sample values before plotting.
All statistics noted used one-tailed Student t tests.
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